☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
PDS Biotech
PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Ca...
October 4, 2023
PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer
March 31, 2023
PDS Biotech Reports P-II Clinical Trial Results of Triple Combination Therapy for Human Papillomavirus-Positive Cancers
December 30, 2022
PDS Biotech Provides Updates of PDS0101 + Keytruda (pembrolizumab) in P-II (VERSATILE-002) Trial for Advanced Head and Neck Cancer
February 3, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.